Key Developments: Ono Pharmaceutical Co Ltd (4528.OS)
6,630JPY
22 May 2013
¥-10 (-0.15%)
¥6,660
¥6,670
¥6,680
¥6,580
171,300
284,038
¥6,720
¥4,275
Latest Key Developments (Source: Significant Developments)
ONO PHARMACEUTICAL CO LTD Announces Application of International Financial Reporting Standards
ONO PHARMACEUTICAL CO LTD announced that it will apply International Financial Reporting Standards (IFRS) as the new accounting method, to replace the current Japan Accounting Standards, starting from the financial report for fiscal year ending March 2014. Full Article
Carna Biosciences Inc Announces Business and Capital Alliances with ONO PHARMACEUTICAL CO LTD and Changes in Shareholding Structure
Carna Biosciences Inc announced that it has formed business and capital alliances with ONO PHARMACEUTICAL CO LTD, on October 4, 2012. Through the business alliance, Carna Biosciences will provide kinase screening services to ONO PHARMACEUTICAL and the two companies will cooperate in the development of new kinase assay. Through the capital alliance, Carna Biosciences will issue a private placement of 14,090 shares of its newly issued common stock to ONO PHARMACEUTICAL, at the price of JPY 20,599 per share (JPY 290,239,910 in total), on October 23, 2012. As a result, the Company will hold 14,090 shares (a 19.35% stake) in Carna Biosciences and become the top shareholder of Carna Biosciences , effective October 23, 2012. Full Article
Galapagos NV's BioFocus And ONO PHARMACEUTICAL CO., LTD. Sign Drug Discovery Agreement-Hugin
Hugin reported that Galapagos NV's service division BioFocus and ONO PHARMACEUTICAL CO., LTD. (Osaka Japan) have signed a new collaboration agreement, focused on discovering novel drugs in the field of CNS disorders. Under the new agreement, BioFocus will use its drug discovery platform to deliver leads and clinical candidates for its client. Financial details were undisclosed. Full Article
Galapagos NV's BioFocus And ONO PHARMACEUTICAL CO., LTD. Announces Additional Collaboration Agreement
Galapagos NV and Ono Pharmaceutical Co., Ltd. announced that they have signed an additional collaboration agreement focused on discovering targets in the field of allergic diseases including atopic dermatitis and bronchial asthma. In the new agreement, Galapagos' service division BioFocus will use its SilenceSelect platform to deliver validated targets to Ono. Ono aims to find modulators for these targets and generate drug candidates. Financial details were undisclosed. Full Article
ONO PHARMACEUTICAL CO., LTD. Amends Consolidated Full-year Forecast for FY 2012
ONO PHARMACEUTICAL CO., LTD. announced that it has reaffirmed the consolidated full-year forecast for revenue of JPY 145,400 million and raised the forecast for operating profit from JPY 36,200 million to JPY 37,600 million, ordinary profit from JPY 38,400 million to JPY 40,000 million, net profit from JPY 18,800 million to JPY 23,800 million and earning per share from JPY 177.33 to JPY 224.49 for the fiscal year ended March 2012. The Company raised the consolidated full-year outlook for operating profit, ordinary profit and net profit due to decreased costs. Full Article
ONO PHARMACEUTICAL CO., LTD. Amends Consolidated Mid-year Outlook for FY 2012
ONO PHARMACEUTICAL CO., LTD. announced that it has raised its consolidated mid-year outlook for revenue from JPY 67,200 million to JPY 70,000 million, operating profit from JPY 15,800 million to JPY 17,600 million and ordinary profit from JPY 17,100 million to JPY 19,000 million, but lowered the outlook for net profit from JPY 11,100 million to JPY 8,300 million and earning per share from JPY 104.70 to JPY 78.29, for the fiscal year ending March 2012. The Company raised the outlook due to the increased sales and lowered the net profit outlook due to the record of loss on revaluation of investment securities, among others. Full Article
ONO PHARMACEUTICAL CO., LTD. Signs License Agreements with Merck KGaA
ONO PHARMACEUTICAL CO., LTD. announced that it has signed a license agreement with Merck KGaA. Under the agreement, ONO PHARMACEUTICAL provides Merck KGaA with the development and marketing right of ONO-4641 in global market. ONO-4641 is a drug for multiple sclerosis treatment developed by ONO PHARMACEUTICAL. For the license, Merck KGaA will pay ONO PHARMACEUTICAL a lump sum of JPY 1,500 million. In addition, ONO PHARMACEUTICAL and Merck KGaA also signed another license agreement. Under the agreement, Merck KGaA provides ONO PHARMACEUTICAL with the development and marketing right of Stimuvax in Japan market. Stimuvax is a kind of drug for cancer mmunotherapy treatment. For the license, ONO PHARMACEUTICAL will pay Merck KGaA a lump sum of EUR 5 million. Full Article
ONO PHARMACEUTICAL CO., LTD. Signs Strategic Alliance Contract with Bristol-Myers Squibb
ONO PHARMACEUTICAL CO., LTD. announced that it has signed a strategic alliance contract with Bristol-Myers Squibb. Under the contract, Bristol-Myers Squibb will be given more territory on the development and commercialization of ONO-4538/BMS-936558, which is an antibody for PD-1. The two companies will also collaborate in the development and commercialization of another medicine product for rheumatoid arthritis treatment in Japan market. Full Article
ONO PHARMACEUTICAL CO., LTD. Signs License Contract with KAI Pharmaceuticals, Inc.
ONO PHARMACEUTICAL CO., LTD. announced that it has signed a license contract with KAI Pharmaceuticals, Inc, which is engaged in the biopharmaceutical businesses in California, on September 15, 2011. Through the contract, the Company will have exclusive rights to develop and commercialize calcimimetic medicine in Japan. Full Article
ONO PHARMACEUTICAL CO., LTD. Signs License Contract with LES LABORATOIRES SERVIER
ONO PHARMACEUTICAL CO., LTD. announced that it has signed a license contract with LES LABORATOIRES SERVIER, which is engaged in the development and research of medicine in France, on September 14, 2011. Through the contract, the Company will have exclusive rights to develop and commercialize the medicine for chronic cardiac failure in Japan. Full Article
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
